(d) whether it is a fact that action gainst none of the producers have een taken by Government so far; nd

(e) what are the details of the producers who have been booked for vercharging of bulk drugs and formulations during 1992?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (c) The names of ulk drugs in respect of which complaints of alleged overcharling of prices received during 1992 are given in he statement attached. (*See* below)

(b), (d) and (e) As and when any omplaint of alleged overcharging of ulk drugs and formulations is received, the same is forwarded to the oncerned State Drug Control Administration for investigation and the ompanies concerned are also asked explain its position. In case the acts are found to be correct after he investigation, by the State Drug ontroller further action under DPCO, 987 as well as under the Essential ommodities Act, 1955, as the case ay be, is initiated.

Statement

r. No.	Name of the Bulk Drug
1.	Vitamin C Plain
2.	Vitamin C Coated
3.	Sodium Ascorbates
4.	Prednisolone
5.	Rifampicin
6.	Erythromycin Stearate
7.	Ampicillin Trihydrate
8.	Trimethoprim
9.	Metronidazole
10.	Metronidazole Benzoate
11.	Pyrazinamide
12.	Di Ethyl Carbamazine Citrate
13.	Ethambutol Hcl
14.	Claxacillin Sodium (Oral Grade)
15.	Chloroquine Phosphate
16.	Sulphamethoxole
17.	Tetracycline Hcl
18.	Analgin
19.	Amoxycillin Trihydrate
20.	Cephalexin.

Ceiling prices of salbutamol formulations

4589. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that M|s. Glaxo is not following the ceiling prices of Salbutamol formulations;

(b) what are the details of formulations based on Salbutamol being marketed by M|s. Glaxo and what are their present price;

(c) whether it is a fact that M|s. Glaxo is selling Salbutamol Inhaler without price approval;

(d) if so, what is the approved price and at what price it is being marketed at present;

(e) whether it is a fact that M|s. Glaxo is marketing number of other formulations without price approval;

(f) if so, what are the prices of all such formulations as approved by Government and the prices at which the company is selling and since when;

(g) whether it is a fact that M|s. Glaxo is marketing number of finished medicines without price approval manufactured by small scale units; and

(h) if so, what are the names of those products?

THE MINISTER OF STATE IN AND FERTILIZERS (SHRI CHINTA AND FERTILIZERS (SHRI CHNTA MOHAN): (a) and (b) A Statement

indicating the details of Salbutamol based formulations being marketed by M|s. Glaxo under brand names is enclosed. (*See* below)

(c) and (d) As per information available M|s. Glaxo are marketing Salbutamol Inhaler under generic name and, therefore, are exempt from price control in respect of this product under DPCO, 1987.

(e) No such instance has come to the notice of Government.

(f) Does not arise.

(g) and (h) The position is being ascertained.

Statement

Sl. No.	Name of the Product	Pack size	Government approved price without E.D. (Rs.)	Company's price without E.D. (Rs.)	
1	2	3	4	5	
1	Ventorlin Syrup . . .	112 ml Bottle	9.12	9.12	Ceiling pack
2	Ventorlin Expectorant (Manufactured by M/s. Kemwell Pvt. Ltd)	120 ml Bottle	9.88	9.88	Non-Ceiling pack
3	Ventorlin 4 mg. Caps (Manufactured by M/s. Themis Lab.)	10's	5.14	5.14	Do.
4	Ventorlin 8 mg. Caps. (Manufactured by M/s. Themis Lab.)	10's	7.33	7.33	Do.

Ceiling prices of medicines.

4590. SHRI H. HANUMANTHAPPA:

SHRIMATI SATYA BAHIN:

Will the PRIME MINISTER be pleased to state:

(a) what were the ceiling prices of Ampicillin caps, Cephalexin Caps, Erythromycin Tabs, Chloramphenicol streptomicin Inj., tetracyline Caps, Chloroquin Tabs, Oxytetracycline Caps and Betamethasone Ointments before the announcement of D.P.C.O. 1987 and what are their present prices;

(b) what is the percentage increase in case of each pack and whether it is a fact that Government failed to contain the prices of these vital medicines;

(c) what steps are being contemplated to contain their prices and whether it is a fact that prices of these medicines would rise by another 30 per cent to 40 per cent if the new policy is announced;

(d) whether it is a fact that the prices of Ampicillin and Cephalexin have not been fixed by Government based on B.I.C.P. study for the last three years; and

(e) if so, the reasons thereof?